In April 2021, Innolcon phaco-emulsification surgical system obtained CE Certification with its excellent anterior chamber stability, efficient and safe intraoperative control, stable and efficient fluid system and ultra-high cost performance. Innolcon is the first Chinese brand of the advanced multi-functional phaco-emulsification surgical system which obtained CE certification and filled the domestic gap in this field.

         As a safe and reliable brand, Innolcon phaco-emulsification surgical system leads the development of the domestic industry and advances further to serve the global market. This has laid a solid foundation for opening up the EU market and deploying the sales and service network through the world.

       With the continuous development of medical technology and living standards, more and more cataract patients not only pursue postoperative vision, but also clear and good vision. According to the survey, the vast majority (93%) of ophthalmologists believe that cataract surgery in China has been upgraded from the traditional rehabilitation surgery to refractive surgery. Refractive surgery can not only solve cataracts, but also cure patients' myopia, hyperopia, astigmatism, presbyopia and other refractive problems.

       The refractive cataract surgery requires precision, which is not only related to the surgical technique, but also depends on the surgical equipment. A powerful phaco-emulsification surgical system is the precondition for accurate refractive cataract surgery.

        In our country, phaco-emulsification equipment has been introduced and promoted from 1992, and mainly relies on imports at present. Therefore, safe, efficient, and cost-effective phaco-emulsification system with excellent performance is highly anticipated.

Innolcon phaco-emulsification surgical system emerged

       In the global technology competition of ophthalmology, Innolcon persisted for years with patience, explored deeply and researched intensively, which led to the birth of today’s Innolcon phaco-emulsification surgical system.

       In May 2021, Innolcon’s whole phaco-emulsification surgical system debuted at the 84th CMEF China International Medical Device Expo, which amazed many industry professionals.

       The live operation demonstrated the excellent performance of Innolcon phaco-emulsification surgical system: greater efficiency, more energy-saving, and reduced thermal damage . Less heat and shorter period of phaco-emulsification can reduce damage to corneal endothelium, ensuring very smooth operation with less blockage .

       Innolcon Phaco-emulsification R&D Director said: In the past, it was considered impossible for a doctor to perform a single phaco-emulsification operation in 4 minutes, but now we can do this with effective phaco-emulsification mode, stable anterior chamber and improved technology. Now the new phaco-emulsification system can solve many difficult problems encountered in the past, such as hard core and dislocated crystals during surgery, broadening indications of the whole field of phaco-emulsification. Most importantly, the risks of phaco-emulsification surgery are minimized, the safety of the surgery is relatively improved, and the patient can benefit more from phaco-emulsification surgery.

       Innolcon General Manager said: We will not stop at the current progress of Innolcon  phaco-emulsification surgical system since scientific and technological innovation is endless. We will continue to explore and contribute to the advancement of cataract phaco-emulsification surgery at home and abroad and the global prevention and treatment of blindness with better research results.